{
    "clinical_study": {
        "@rank": "117611", 
        "arm_group": {
            "arm_group_label": "BI-505", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to investigate the effect of BI-505 on tumor burden in patients\n      diagnosed with smoldering multiple myeloma."
        }, 
        "brief_title": "A Phase II Study of BI-505 in Smoldering Multiple Myeloma", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Smoldering Multiple Myeloma", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Myeloma", 
                "Neoplasms, Plasma Cell"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of Smoldering multiple myeloma based on the International Myeloma Working\n             Group criteria:\n\n               -  Serum M-protein greater than or equal to 3 g/dL and/or bone marrow plasma cells\n                  greater than or equal to 10 percent.\n\n               -  Absence of end-organ damage such as lytic bone lesions, anemia, hypercalcemia or\n                  renal failure that can be attributed to a plasma cell proliferative disorder.\n\n          -  Male or female, 18 years or older.\n\n          -  Eastern Cooperative Oncology Group (ECOG) Performance status of 0-1.\n\n        Exclusion Criteria:\n\n          -  Patients with a diagnosis of symptomatic multiple myeloma or a clinical suspicion of\n             an ongoing progression into symptomatic multiple myeloma.\n\n          -  Prior or current treatment having a proven or potential impact on myeloma cell\n             proliferation or survival (including conventional chemotherapies, biological\n             therapies, immunomodulatory drugs, or proteasome inhibitors), as judged by the\n             Investigator.\n\n          -  Severe other conditions."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01838369", 
            "org_study_id": "12-BI-505-02"
        }, 
        "intervention": {
            "arm_group_label": "BI-505", 
            "intervention_name": "BI-505", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 23, 2013", 
        "location": {
            "contact": {
                "email": "maria.hector@skane.se", 
                "last_name": "Maria Hector, Study Nurse", 
                "phone": "+46 (0)46 176113"
            }, 
            "contact_backup": {
                "email": "andreas.bjorklund@skane.se", 
                "last_name": "Andreas Bj\u00f6rklund, Study Nurse", 
                "phone": "+46 (0)46 173568"
            }, 
            "facility": {
                "address": {
                    "city": "Lund", 
                    "country": "Sweden", 
                    "zip": "SE-22185"
                }, 
                "name": "Department of Hemtaology, Sk\u00e5ne University Hospital"
            }, 
            "investigator": {
                "last_name": "Markus Hansson, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Sweden"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Single-arm, Open-label, Phase 2 Clinical Trial Evaluating Disease Response Following Treatment With BI-505, a Human Anti-Intercellular Adhesion Molecule 1 Monoclonal Antibody, In Patients With Smoldering Multiple Myeloma", 
        "overall_contact": {
            "email": "elisabeth.sonesson@bioinvent.com", 
            "last_name": "Elisabeth Sonesson, PhD", 
            "phone": "+46 46 2868646"
        }, 
        "overall_official": {
            "affiliation": "Department of Hematology,Sk\u00e5ne University Hospital", 
            "last_name": "Markus Hansson, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Sweden: Medical Products Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "To assess the change in disease activity measured as M-protein levels in serum/urine following BI-505 treatment compared to base line according to the International Myeloma Working Group (IMWG) uniform response criteria", 
            "safety_issue": "No", 
            "time_frame": "M-protein will be measured at screening, prior to each dose and at end of study visit, for up to 19 weeks."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01838369"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Safety will be assessed by measuring the following clinical safety parameters; Adverse events, vital signs, clinical laboratory tests, ECG and immunogenicity.", 
                "measure": "The clinical safety of BI-505 will be assessed by reporting the numbers of AEs, the severity and the relationship to IMP.", 
                "safety_issue": "Yes", 
                "time_frame": "At each visit and up to 28 days after the last dose."
            }, 
            {
                "measure": "The pharmacokinetic profile of BI-505 will be determined by calculating the following pharmacokinetic parameters: AUC, % AUCex, Cmax, Tmax, CL, Vss and T1/2.", 
                "safety_issue": "No", 
                "time_frame": "Up to 28 days after the last dose."
            }, 
            {
                "measure": "The pharmacodynamics of BI-505 will be assessed by measuring soluble biomarkers and ICAM-1 saturation on bone marrow plasma cells.", 
                "safety_issue": "No", 
                "time_frame": "Up to 28 days after the last dose."
            }, 
            {
                "measure": "The immunogenicity profile of BI-505 will be assessed by measuring antibodies towards BI-505.", 
                "safety_issue": "Yes", 
                "time_frame": "Prior to first dose and at 28 days after the final dose."
            }
        ], 
        "source": "BioInvent International AB", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "BioInvent International AB", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}